Suckerin Colloids and Hydrogels With Low Immunogenicity as Resorbable and Hemostatic Tissue Adhesives for Wound Healing

Why It Matters

The breakthrough offers a safer, more effective alternative to existing surgical glues, potentially reshaping the wound‑care market and accelerating adoption of bio‑derived adhesives in clinical practice.

Key Takeaways

• Suckerin-12 hydrogels outperform fibrin glue in hemostasis.
• Low immunogenicity enables safer wound‑closure applications.
• Riboflavin crosslinking preserves β‑sheet elasticity.
• Scalable recombinant production reduces manufacturing costs.
• Transcriptomics reveal enhanced angiogenesis and re‑epithelialization.

Pulse Analysis

The global tissue‑adhesive market, projected to exceed $2 billion by 2030, has been hampered by reliance on animal‑derived fibrin glues and synthetic polymers that can trigger immune reactions or lose strength in wet environments. By harnessing squid‑derived suckerin proteins—nature’s own high‑adhesion material—researchers have created a bio‑adhesive that not only matches but surpasses the wet‑bond strength of mussel‑inspired counterparts, addressing a critical performance gap for surgeons and wound‑care providers.

Key to the material’s success is its recombinant production, which enables precise control over protein composition and large‑scale manufacturing. The hydrogels are crosslinked using riboflavin‑mediated di‑tyrosine bonds, a mild, photo‑activated process that retains the protein’s β‑sheet‑rich secondary structure, delivering elasticity comparable to native tissue. In vivo studies demonstrated rapid hemostasis, accelerated skin cell migration, and superior wound closure relative to fibrin glue, while exhibiting negligible cytotoxicity, hemolysis, and immune activation—attributes essential for regulatory clearance and clinical acceptance.

From a commercial perspective, the low immunogenic profile and scalable bioprocessing lower production costs and simplify supply chain logistics, making suckerin‑based adhesives attractive to medical‑device firms seeking differentiated, eco‑friendly products. The transcriptomic evidence of enhanced angiogenic and proliferative pathways suggests broader therapeutic applications, including internal surgical seals and regenerative dressings. As hospitals prioritize patient safety and cost‑effectiveness, the adoption of such next‑generation bio‑glues could drive significant market share gains and stimulate further investment in protein‑engineered biomaterials.